SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Domchek Susan M) "

Sökning: WFRF:(Domchek Susan M)

  • Resultat 21-25 av 25
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Yang, Xin, et al. (författare)
  • Cancer risks associated with germline PALB2 pathogenic variants : An international study of 524 families
  • 2020
  • Ingår i: Journal of Clinical Oncology. - 0732-183X. ; 38:7, s. 674-685
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 3 1022). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
  •  
22.
  •  
23.
  •  
24.
  • Kaufman, Bella, et al. (författare)
  • Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
  • 2015
  • Ingår i: Journal of Clinical Oncology. - 1527-7755. ; 33:3, s. 134-244
  • Tidskriftsartikel (refereegranskat)abstract
    • Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.
  •  
25.
  • Tutt, Andrew, et al. (författare)
  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
  • 2010
  • Ingår i: The Lancet. - 1474-547X. ; 376:9737, s. 235-244
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial signal of efficacy in BRCA-deficient ovarian cancers have been reported. We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer. Methods Women (aged years) with confirmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were assigned to two sequential cohorts in a phase 2 study undertaken in 16 centres in Australia, Germany, Spain, Sweden, the UK, and the USA. The first cohort (n=27) was given continuous oral olaparib at the maximum tolerated dose (400 mg twice daily), and the second (n=27) was given a lower dose (100 mg twice daily). The primary efficacy endpoint was objective response rate (ORR). This study is registered with ClinicalTrials.gov, number NCT00494234. Findings Patients had been given a median of three previous chemotherapy regimens (range 1-5 in cohort 1, and 2-4 in cohort 2). ORR was 11 (41%) of 27 patients (95% CI 25-59) in the cohort assigned to 400 mg twice daily, and six (22%) of 27 (11-41) in the cohort assigned to 100 mg twice daily. Toxicities were mainly at low grades. The most frequent causally related adverse events in the cohort given 400 mg twice daily were fatigue (grade 1 or 2, 11 [41%]; grade 3 or 4, four [15%]), nausea (grade 1 or 2, 11 [41%]; grade 3 or 4, four [15%]), vomiting (grade 1 or 2, three [11%]; grade 3 or 4, three [11%]), and anaemia (grade 1 or 2, one [4%]; grade 3 or 4, three [11%]). The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 11 [41%]; none grade 3 or 4) and fatigue (grade 1 or 2, seven [26%]; grade 3 or 4, one [4%]). Interpretation The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair. Toxicity in women with BRCA1 and BRCA2 mutations was similar to that reported previously in those without such mutations.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-25 av 25
Typ av publikation
tidskriftsartikel (25)
Typ av innehåll
refereegranskat (24)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Domchek, Susan M. (24)
Chenevix-Trench, Geo ... (21)
Antoniou, Antonis C. (21)
Nevanlinna, Heli (20)
Easton, Douglas F. (20)
McGuffog, Lesley (20)
visa fler...
Couch, Fergus J. (19)
Benitez, Javier (18)
Offit, Kenneth (18)
Frost, Debra (18)
Hamann, Ute (17)
Healey, Sue (17)
Nathanson, Katherine ... (17)
Godwin, Andrew K. (17)
Radice, Paolo (16)
Stoppa-Lyonnet, Domi ... (16)
Mazoyer, Sylvie (16)
Friedman, Eitan (16)
Peterlongo, Paolo (16)
Osorio, Ana (16)
John, Esther M (15)
Neuhausen, Susan L (15)
Daly, Mary B. (15)
Meindl, Alfons (15)
Laitman, Yael (15)
Singer, Christian F. (15)
Andrulis, Irene L. (14)
Evans, D. Gareth (14)
Jakubowska, Anna (14)
Schmutzler, Rita K. (14)
Simard, Jacques (14)
Thomassen, Mads (14)
Manoukian, Siranoush (14)
Garber, Judy (14)
Devilee, Peter (13)
Sinilnikova, Olga M. (13)
Rookus, Matti A. (13)
Lubinski, Jan (13)
Caldes, Trinidad (13)
Greene, Mark H. (13)
Hansen, Thomas V. O. (13)
Lazaro, Conxi (13)
Buys, Saundra S. (12)
Ehrencrona, Hans (12)
Loman, Niklas (12)
Eccles, Diana (12)
Izatt, Louise (12)
Hogervorst, Frans B. ... (12)
Spurdle, Amanda B. (12)
Southey, Melissa (12)
visa färre...
Lärosäte
Lunds universitet (22)
Karolinska Institutet (10)
Umeå universitet (4)
Uppsala universitet (3)
Göteborgs universitet (2)
Linköpings universitet (1)
Språk
Engelska (25)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (25)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy